Screener
Artiva Biotherapeutics, Inc. ARTV Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -36.6%— | -67.9%— | -56.5%— | -48%— | —— | |
| Return on invested capital | -101.9%— | -80.5%— | -70.6%— | -62.7%— | —— | |
| Liquidity | ||||||
| Current ratio | 24.2×+10.3× | 8.2×-5.8× | 8.6×-6.8× | 11.6×+0.3× | 13.8×+9.2× | |
| Leverage | ||||||
| Debt-to-equity | 0×-0.1× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×— | |
| Per Share | ||||||
| Book value per share | $8.82+44.2% | $3.56-48.7% | $4.50-72.9% | $5.28-50.4% | $6.11+103% | |
| Valuation | ||||||
| Market capitalization | $331.96M+361% | $159.18M+118% | $105.3M-57.0% | $70.1M— | $39.22M— | |
| Price / book | 1×+0.4× | 1.8×+1.4× | 1×-0.4× | 0.5×— | 0.3×— |
FAQ
- Where do Artiva Biotherapeutics, Inc.'s ratios come from?
- Every ratio is computed from Artiva Biotherapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.